文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

基于三维蒙特卡洛与锝-99m抗粒细胞抗体SPECT/CT定位的177Lu-PSMA治疗骨髓剂量学研究

3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT.
PubMed 文献 · EJNMMI Res · 2019-08-14

该研究对10例mCRPC患者的11个177Lu-PSMA-617治疗周期,利用蒙特卡洛模拟计算骨髓吸收剂量,比较两种骨髓分布假设(生理分布MC1与病灶处活性骨髓位移MC2)及传统S值法SMIRD。结果显示MC2与血小板下降相关性最强(r=-0.71,p=0.01),且2例患者经99mTc-抗粒细胞抗体SPECT/CT验证的骨髓位移使剂量较MC1降低40%和41%。

要点

  • MC1、MC2和SMIRD的中位骨髓吸收剂量分别为130、37和11 mGy/GBq。
  • MC2与血小板下降相关性最强(r=-0.71,p=0.01),MC1为r=-0.63(p=0.04)。
  • 99mTc-抗粒细胞抗体SPECT/CT可无创定位活性骨髓,提示病灶处骨髓位移。

核心结论

  • 基于蒙特卡洛的骨髓剂量模型给出更高吸收剂量,但MC2模型下所有剂量仍低于2 Gy。
  • MC1可能因忽略骨髓位移而高估吸收剂量,图像引导的骨髓定位可能有益。

研究设计与样本

  • 基于11个177Lu-PSMA-617治疗周期(10例患者,10个首周期)的回顾性剂量学研究。
  • 患者接受治疗前68Ga-PSMA-11 PET/CT、腹部定量177Lu SPECT(24、48、72小时)及24小时全身平面显像。
  • 将患者特异性三维感兴趣区分割并填入177Lu活性信息,结合患者CT导入FLUKA蒙特卡洛程序模拟骨髓吸收剂量。
  • 分别假设ICRP 110参考男性生理骨髓分布(MC1)和活性骨髓从骨病灶直接位置位移(MC2),并与S值法(SMIRD)比较。
  • 对2例患者额外行治疗前99mTc-抗粒细胞抗体SPECT/CT用于骨髓定位。

主要发现

  • MC1、MC2和SMIRD的中位骨髓吸收剂量分别为130、37和11 mGy/GBq。
  • 骨髓吸收剂量与血小板计数下降呈显著强相关,MC1:r=-0.63(p=0.04);MC2:r=-0.71(p=0.01);SMIRD:r=-0.62(p=0.04)。
  • 2例经99mTc-抗粒细胞抗体SPECT/CT定位的患者均显示活性骨髓从病灶直接位置位移,与MC2模型相似,骨髓吸收剂量较MC1分别降低40%和41%。

临床怎么用

  • 在177Lu-PSMA治疗骨髓剂量评估中,可考虑结合功能影像(如99mTc-抗粒细胞抗体SPECT/CT)定位活性骨髓以校正病灶相关骨髓位移。
  • 基于S值的骨髓剂量可能因忽略患者特异性骨髓分布而低估或高估剂量,蒙特卡洛模拟可提供更个体化评估。

局限性

  • 样本量小(10例患者、11个治疗周期),仅2例患者进行了99mTc-抗粒细胞抗体SPECT/CT骨髓定位。
  • MC1和MC2为基于假设的骨髓分布模型,尚未经组织学验证。
  • 需要未来研究进一步支持图像引导骨髓定位对血液毒性预测的改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The bone marrow (BM) is a main risk organ during Lu-177-PSMA ligand therapy of metastasized castration-resistant prostate cancer (mCRPC) patients. So far, BM dosimetry relies on S values, which are pre-computed for reference anatomies, simplified activity distributions, and a physiological BM distribution. However, mCRPC patients may show a considerable bone lesion load, which leads to a heterogeneous and patient-specific activity accumulation close to BM-bearing sites. Furthermore, the patient-specific BM distribution might be significantly altered in the presence of bone lesions. The aim was to perform BM absorbed dose calculations through Monte Carlo (MC) simulations and to investigate the potential value of image-based BM localization. This study is based on 11 Lu-177-PSMA-617 therapy cycles of 10 patients (10 first cycles), who obtained a pre-therapeutic Ga-68-PSMA-11 PET/CT; quantitative Lu-177 SPECT acquisitions of the abdomen 24 (+CT), 48, and 72 h p.i.; and a Lu-177 whole-body planar acquisition at 24 h post-therapy. Patient-specific 3D volumes of interest were segmented from the Ga-68-PSMA-11 PET/CT, filled with activity information from the Lu-177 data, and imported into the FLUKA MC code together with the patient CT. MC simulations of the BM absorbed dose were performed assuming a physiological BM distribution according to the ICRP 110 reference male (MC1) or a displacement of active BM from the direct location of bone lesions (MC2). Results were compared with those from S values (SMIRD). BM absorbed doses were correlated with the decrease of lymphocytes, total white blood cells, hemoglobin level, and platelets. For two patients, an additional pre-therapeutic Tc-99m-anti-granulocyte antibody SPECT/CT was performed for BM localization. RESULTS: Median BM absorbed doses were 130, 37, and 11 mGy/GBq for MC1, MC2, and SMIRD, respectively. Significant strong correlation with the decrease of platelet counts was found, with highest correlation for MC2 (MC1: r = - 0.63, p = 0.04; MC2: r = - 0.71, p = 0.01; SMIRD: r = - 0.62, p = 0.04). For both investigated patients, BM localization via Tc-99m-anti-granulocyte antibody SPECT/CT indicated a displacement of active BM from the direct location of lesions similar to model MC2 and led to a reduction in the BM absorbed dose of 40 and 41% compared to MC1. CONCLUSION: Higher BM absorbed doses were observed for MC-based models; however, for MC2, all absorbed doses were still below 2 Gy. MC1 resulted in critical values for some patients, but is suspected to yield strongly exaggerated absorbed doses by neglecting bone marrow displacement. Image-based BM localization might be beneficial, and future studies are recommended to support an improvement for the prediction of hematoxicities.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Gosewisch A, Ilhan H, Tattenberg S, et al. 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT. EJNMMI Res. 2019. PMID: 31414241. doi:10.1186/s13550-019-0548-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。